Cargando…

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada

In Quebec, Canada, eligibility for palivizumab (PVZ) immunoprophylaxis was expanded in fall 2016 to include healthy-full-term (HFT) infants residing in the circumpolar region of Nunavik and aged <3 months at the start of the RSV season or born during the season. This study assessed the effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilca, Rodica, Billard, Marie-Noëlle, Zafack, Joseline, Papenburg, Jesse, Boucher, François D., Charest, Hugues, Rochette, Marie, De Serres, Gaston
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484550/ https://www.ncbi.nlm.nih.gov/pubmed/32953425 http://dx.doi.org/10.1016/j.pmedr.2020.101180

Ejemplares similares

Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec
por: Lorcy, Armelle, et al.
Publicado: (2020)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Respiratory syncytial virus contributes to more severe respiratory morbidity than influenza in children < 2 years during seasonal influenza peaks
por: Amini, Rachid, et al.
Publicado: (2019)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Trends of Hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003
por: Canuel, Magalie, et al.
Publicado: (2007)

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada
por: Gilca, Rodica, et al.
Publicado: (2011)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
por: de Souza, Roseane Porfírio, et al.
Publicado: (2019)

Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015
por: Gilca, Rodica, et al.
Publicado: (2015)

Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?
por: Quinn, Lauren A., et al.
Publicado: (2021)

Assessment of the implementation fidelity of the Arctic Char Distribution Project in Nunavik, Quebec
por: Gautier, Lara, et al.
Publicado: (2016)

Inuit interpreters engaged in end-of-life care in Nunavik, Northern Quebec
por: Hordyk, Shawn Renee, et al.
Publicado: (2017)

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials
por: Zafack, Joseline Guetsop, et al.
Publicado: (2019)

Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity
por: Billard, Marie-Noëlle, et al.
Publicado: (2017)

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

Burden of respiratory infections and otitis media in the Inuit population of Nunavik, Quebec, Canada
por: De Wals, Philippe, et al.
Publicado: (2020)

Translational research to reduce trans-fat intakes in Northern Québec (Nunavik) Inuit communities: a success story?
por: Counil, Émilie, et al.
Publicado: (2012)

Inuit women's attitudes and experiences towards cervical cancer and prevention strategies in Nunavik, Quebec
por: Cerigo, Helen, et al.
Publicado: (2012)

Laboratory Features of Trichinellosis and Eosinophilia Threshold for Testing, Nunavik, Quebec, Canada, 2009–2019
por: Harrison, Luke B., et al.
Publicado: (2022)

Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada
por: Baz, Mariana, et al.
Publicado: (2012)

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?
por: Sáfadi, Marco Aurélio P.
Publicado: (2014)

Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada
por: Cerigo, Helen, et al.
Publicado: (2013)

Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010
por: Le Meur, Jean-Baptiste, et al.
Publicado: (2014)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Chemical Composition and Antiplasmodial Activity of the Essential Oil of Rhododendron subarcticum Leaves from Nunavik, Québec, Canada
por: Séguin, Jean-Christophe, et al.
Publicado: (2023)

School Absenteeism As an Adjunct Surveillance Indicator: Experience during the Second Wave of the 2009 H1N1 Pandemic in Quebec, Canada
por: Kom Mogto, Christelle Aïcha, et al.
Publicado: (2012)

Human Metapneumovirus Infections in Hospitalized Children
por: Boivin, Guy, et al.
Publicado: (2003)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

The epidemiology and risk factors of respiratory syncytial virus and its impact on the timing of immunoprophylaxis
por: Jeena, Prakash Mohan
Publicado: (2018)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
por: Fang, Li-Ching, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eih9chmr8ufm8f4g7j3topco2b